Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Sunday. The firm issued a hold rating on the stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a report on Tuesday, March 4th. Lake Street Capital dropped their price objective on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th.

Ekso Bionics Stock Performance

Shares of NASDAQ:EKSO opened at $0.41 on Friday. The firm’s 50 day simple moving average is $0.45 and its 200-day simple moving average is $0.65. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. Ekso Bionics has a one year low of $0.34 and a one year high of $1.53. The firm has a market cap of $11.96 million, a PE ratio of -0.63 and a beta of 1.33.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $5.05 million. As a group, equities analysts predict that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.